This epidemiological study is a unique collaboration between The University of Manchester, the British Society for Rheumatology and the pharmaceutical industry.
All consultant rheumatologists in the UK who prescribe biologic, biosimilar or JAK inhibitors can participate in the register, supported by allied health professionals.
The register is supported by a dedicated team of staff based at the Biologic Studies Group at The University of Manchester.
The team make sure that all aspects of the study run smoothly, including data collection and management, local investigator liaison, patient and public involvement/engagement, analysis of data and report preparation.
In addition, the team provides pharmacovigilance/safety monitoring for the pharmaceutical companies who manufacture the biologic/biosimilar and other targeted therapy drugs used to treat rheumatoid arthritis to provide data to the regulatory bodies such as the Medicines and Healthcare Regulatory Agency (MHRA) and European Medicines Agency (EMA).